T. T. Duong

Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.

D. Walters, P. Darke, W. Schleif, 1996, Journal of medicinal chemistry.

Nonpeptidal P2 Ligands for HIV Protease Inhibitors: Structure‐Based Design, Synthesis, and Biological Evaluation.

Arun K. Ghosh, D. Walters, P. Darke, 1996 .

The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors.

P. Darke, M. Holloway, C. Culberson, 1994, Journal of medicinal chemistry.

Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands.

P. Darke, M. Holloway, A. Ghosh, 1993, Journal of medicinal chemistry.

Enhanced Degradation of Phenolic Compounds in Coal Gasification Wastewater by Methods of Microelectrolysis Fe-C and Anaerobic-Anoxic—Oxic Moving Bed Biofilm Reactor (A2O-MBBR)

V. T. Nguyen, Hong Tham Nguyen Thi, T. T. Duong, 2020, Processes.

3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors.

E A Emini, Arun K. Ghosh, P. Darke, 1993, Journal of medicinal chemistry.

Potent HIV Protease Inhibitors: The Development of Tetrahydrofuranylglycines as Novel P2‐Ligands and Pyrazine. Amides as P3‐Ligands.

Arun K. Ghosh, P. Anderson, P. Darke, 1993 .